The effects of rivastigmine plus selegiline on brain acetylcholinesterase, (Na+, K+)-, Mg2+-ATPase activities, antioxidant status, and learning performance of aged rats
Haris Carageorgiou1, Antonios C Sideris1, Ioanna Messari1, Chrissoula I Liakou1, Stylianos Tsakiris21Department of Pharmacology, 2Department of Physiology, Medical School, University of Athens, Athens, GreeceAbstract: We investigated the effects of rivastigmine (a cholinesterase inhibitor) and seleg...
Guardado en:
Autores principales: | Haris Carageorgiou, Antonios C Sideris, Ioanna Messari, Chrissoula I Liakou, Stylianos Tsakiris |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b6f106d167f247ba98ab073ab0968dd3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia
por: Kandiah N, et al.
Publicado: (2017) -
Rivastigmine in Chinese patients with subcortical vascular dementia
por: Vincent Mok, et al.
Publicado: (2007) -
Rivastigmine in the treatment of Alzheimer's disease: an update
por: Maria Luisa Onor, et al.
Publicado: (2007) -
Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report
por: Kitaichi Y, et al.
Publicado: (2013) -
Rivastigmine for the treatment of dementia associated with Parkinson’s disease
por: Jennifer L Reingold, et al.
Publicado: (2007)